150 related articles for article (PubMed ID: 12140388)
1. Adjuvant therapy of melanoma: what's new?
Ascierto PA; Palmieri G; Daponte A; Melucci MT; Satriano RA; Mozzillo N; Castello G;
Melanoma Res; 2002 Jun; 12(3):293-6. PubMed ID: 12140388
[No Abstract] [Full Text] [Related]
2. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
Bajetta E
Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
[No Abstract] [Full Text] [Related]
3. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma.
Kirkwood JM; Tarhini AA; Moschos SJ; Panelli MC
Nat Clin Pract Oncol; 2008 Jan; 5(1):2-3. PubMed ID: 18030300
[No Abstract] [Full Text] [Related]
5. Report on the 4th International Conference on the Adjuvant Therapy of Malignant Melanoma held at the Royal College of Physicians, London, UK, 15-16 March 2002.
Retsas S; Falkson C; Spitler L
Melanoma Res; 2002 Jun; 12(3):A1-4. PubMed ID: 12140389
[No Abstract] [Full Text] [Related]
6. Malignant melanoma: non-metastatic.
Crosby D; Crosby T; Mason M
Clin Evid; 2002 Jun; (7):1519-29. PubMed ID: 12230768
[No Abstract] [Full Text] [Related]
7. Multidisciplinary treatment of primary melanoma.
Yao K; Balch G; Winchester DJ
Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma.
Puente Vázquez J; González Larriba JL
Clin Transl Oncol; 2007 Mar; 9(3):125-6. PubMed ID: 17403622
[No Abstract] [Full Text] [Related]
9. New approaches to the systemic treatment of melanoma.
Chowdhury S; Vaughan MM; Gore ME
Cancer Treat Rev; 1999 Oct; 25(5):259-70. PubMed ID: 10544070
[TBL] [Abstract][Full Text] [Related]
10. Update on the role of adjuvant interferon for high risk melanoma.
Agarwala SS; Kirkwood JM
Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha induced Raynaud's syndrome.
Kruit WH; Eggermont AM; Stoter G
Ann Oncol; 2000 Nov; 11(11):1501-2. PubMed ID: 11142493
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
[TBL] [Abstract][Full Text] [Related]
13. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
14. Interferon-induced obsessive-compulsive symptoms in malignant melanoma.
Mavrogiorgou P; Juckel G
Pharmacopsychiatry; 2012 Jan; 45(1):28-30. PubMed ID: 21989604
[TBL] [Abstract][Full Text] [Related]
15. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant interferon: extended follow-up times needed?
Thoren FB; Strannegård Ö
Lancet Oncol; 2011 May; 12(5):419. PubMed ID: 21536217
[No Abstract] [Full Text] [Related]
17. Adjuvant therapy in melanoma.
Mohr P; Weichenthal M; Hauschild A
Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
[TBL] [Abstract][Full Text] [Related]
18. [Recombinant α-2 interferon in preventing the progression of melanoma].
Korovin SI; Kukushkina MN; Palivets AIu; Fil'chakov FV; Shumilina ES; Ostafĭchuk VV
Lik Sprava; 2013 Dec; (8):21-30. PubMed ID: 25726673
[TBL] [Abstract][Full Text] [Related]
19. What can we learn from phase II adjuvant trials in melanoma?
Keilholz U; Suciu S; Eggermont AM
Br J Cancer; 2000 Jul; 83(1):6-7. PubMed ID: 10883660
[No Abstract] [Full Text] [Related]
20. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients.
Domingo-Domènech J; Castel T; Auge JM; Garcia-Albeniz XA; Conill C; Puig S; Vilella R; Matas J; Malvehy J; Gascón P; Mellado B; Molina R
Tumour Biol; 2007; 28(5):264-72. PubMed ID: 17962723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
